SciClone will channel Medicines Co. drugs in China

The Medicines Co. (NASDAQ:MDCO) granted SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) exclusive rights to promote cardiovascular drugs Cleviprex

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE